Alliance with AstraZeneca Korea positive for Green Cross

Published: 2011-03-29 06:57:00

Updated: 2011-03-29 06:57:00

Green Cross Corp. said Friday it has signed an agreement with AstraZeneca Korea to co-market Atacand (candesartan cilexetil), angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Analysts say the strategic alliance between Green Cross and AstraZeneca Korea is likel...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK